A Study to Compare Health Care Costs Between Apixaban and Low Molecular Weight Heparin in Patients With Venous Thromboembolism and Cancer
Completed
- Conditions
- Thromboembolism
- Registration Number
- NCT05643885
- Lead Sponsor
- Pfizer
- Brief Summary
The purpose of this study is to evaluate the health care resource utilization and costs associated with treating patients diagnosed with cancer and venous thromboembolism with apixaban or low molecular weight heparin. This is a retrospective database analysis of health care claims data. All-cause costs as well as costs associated with recurrent VTE, major bleeding, and clinically relevant nonmajor bleeding will be assessed.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 10000
Inclusion Criteria
- Venous thromboembolism (VTE) diagnosis between January 1 2017 and October 31 2021
- Evidence of active cancer
- At least 1 claim for apixaban or low molecular weight heparin (LMWH)
- Age 18 years or older
Exclusion Criteria
- diagnosis of atrial fibrillation/flutter
- procedure for mechanical heart valve or inferior vena cava filter
- VTE diagnosis in the baseline period
- anticoagulant therapy in the baseline period
- pregnancy
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Total all-cause Healthcare Costs: Total Healthcare Costs Per Person Per Month (PPPM) from index date up to the earliest of health plan disenrollment, treatment discontinuation or switch, or end of study period. Assessed up to 60 months All-cause Healthcare Costs: Outpatient Pharmacy Costs Per Person Per Month from index date up to the earliest of health plan disenrollment, treatment discontinuation or switch, or end of study period. Assessed up to 60 months All-cause Healthcare Costs: Outpatient Medical Costs Per Person Per Month from index date up to the earliest of health plan disenrollment, treatment discontinuation or switch, or end of study period. Assessed up to 60 months All-cause Healthcare Costs: Hospitalization Costs Per Person Per Month from index date up to the earliest of health plan disenrollment, treatment discontinuation or switch, or end of study period. Assessed up to 60 months Recurrent Venous Thromboembolism (VTE) related Costs: Total costs Per Person Per Month from event date up to the earliest of health plan disenrollment, treatment discontinuation or switch, or end of study period. Assessed up to 60 months Recurrent VTE related costs: Outpatient Medical Costs Per Person Per Month from event date up to the earliest of health plan disenrollment, treatment discontinuation or switch, or end of study period. Assessed up to 60 months Recurrent VTE related Costs: Hospitalization Costs Per Person Per Month from event date up to the earliest of health plan disenrollment, treatment discontinuation or switch, or end of study period. Assessed up to 60 months Major Bleeding Related Costs: Total Costs Per Person Per Month from event date up to the earliest of health plan disenrollment, treatment discontinuation or switch, or end of study period. Assessed up to 60 months Major Bleeding Related Costs: Outpatient Medical Costs Per Person Per Month from event date up to the earliest of health plan disenrollment, treatment discontinuation or switch, or end of study period. Assessed up to 60 months Major Bleeding Related Costs: Hospitalization Costs Per Person Per Month from event date up to the earliest of health plan disenrollment, treatment discontinuation or switch, or end of study period. Assessed up to 60 months Clinically Relevant Non-Major Bleeding Related Costs: Total Costs Per Person Per Month from event date up to the earliest of health plan disenrollment, treatment discontinuation or switch, or end of study period. Assessed up to 60 months Clinically relevant Non-Major Bleed Related Costs: Outpatient Medical Costs Per Person Per Month from event date up to the earliest of health plan disenrollment, treatment discontinuation or switch, or end of study period. Assessed up to 60 months Clinically Relevant Non-Major Bleeding Related Costs: Hospitalization Costs Per Person Per Month from event date up to the earliest of health plan disenrollment, treatment discontinuation or switch, or end of study period. Assessed up to 60 months
- Secondary Outcome Measures
Name Time Method All-cause Health Care Resource Utilization: Number of Hospitalizations Per Person Per Month from index date up to the earliest of health plan disenrollment, treatment discontinuation or switch, or end of study period. Assessed up to 60 months All-cause Health Care Resource Utilization: Number of Emergency Room Visits Per Person Per Month from index date up to the earliest of health plan disenrollment, treatment discontinuation or switch, or end of study period. Assessed up to 60 months All-cause Health Care Resource Utilization: Number of Outpatient Medical Visits Per Person Per Month from index date up to the earliest of health plan disenrollment, treatment discontinuation or switch, or end of study period. Assessed up to 60 months All-cause Health Care Resource utilization: Number of Prescription Fills Per Person Per Month from index date up to the earliest of health plan disenrollment, treatment discontinuation or switch, or end of study period. Assessed up to 60 months Recurrent Venous Thromboembolism (VTE) Related Health Care Resource Utilization: Number of Hospitalizations Per Person Per Month from event date up to the earliest of health plan disenrollment, treatment discontinuation or switch, or end of study period. Assessed up to 60 months Recurrent VTE Related Health Care Resource Utilization: Number of Outpatient Medical Visits Per Person Per Month from event date up to the earliest of health plan disenrollment, treatment discontinuation or switch, or end of study period. Assessed up to 60 months Recurrent VTE Related Health Care Resource Utilization: Number of Emergency Room Visits Per Patient Per Month from event date up to the earliest of health plan disenrollment, treatment discontinuation or switch, or end of study period. Assessed up to 60 months Major Bleeding Related Health Care Resource Utilization: Number of Hospitalizations Per Person Per Month from event date up to the earliest of health plan disenrollment, treatment discontinuation or switch, or end of study period. Assessed up to 60 months Major Bleeding Related Health Care Resource Utilization: Number of Outpatient Medical Visits Per Person Per Month from event date up to the earliest of health plan disenrollment, treatment discontinuation or switch, or end of study period. Assessed up to 60 months Major Bleeding Related Health Care Resource Utilization: Number of Emergency Room Visits Per Person Per Month from event date up to the earliest of health plan disenrollment, treatment discontinuation or switch, or end of study period. Assessed up to 60 months Clinically Relevant Non-Major Bleeding Related Health Care Resource Utilization: Number of Hospitalizations Per Person Per Month from event date up to the earliest of health plan disenrollment, treatment discontinuation or switch, or end of study period. Assessed up to 60 months Clinically Relevant Non-Major Bleeding Related Health Care Resource Utilization: Number of Outpatient Medical Visits Per Person Per Month from event date up to the earliest of health plan disenrollment, treatment discontinuation or switch, or end of study period. Assessed up to 60 months Clinically Relevant Non-Major Bleeding Health Care Resource Utilization: Number of Emergency Room Visits Per Person Per Month from event date up to the earliest of health plan disenrollment, treatment discontinuation or switch, or end of study period. Assessed up to 60 months
Trial Locations
- Locations (1)
Pfizer Investigational
🇺🇸New York, New York, United States